Curaleaf Holdings (CURLF) Cost of Revenue (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Cost of Revenue of $166.9 million for Q1 2026, up 10.51% year-on-year from $151.1 million in Q1 2025, and up 4.46% on a QoQ basis from $159.8 million in Q4 2025.
Curaleaf Holdings (CURLF) Cost of Revenue (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Cost of Revenue for 8 consecutive years, with $166.9 million the latest figure, recorded in Q1 2026.
- Quarterly Cost of Revenue rose 10.51% year-over-year to $166.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $649.2 million (down 2.6% YoY) and the FY2025 annual result came in at $637.1 million, down 8.13% from the prior year.
- Cost of Revenue improved to $166.9 million in Q1 2026 per CURLF's latest filing, from $159.8 million in the prior quarter.
- Over the last five years, Cost of Revenue for CURLF reached as high as $274.4 million in Q4 2022 and fell as low as $189077.0 in Q4 2023.
- A 5-year average of $163.3 million and a median of $163.7 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue sank 99.93% — and 2024, when it jumped 86456.8%.
- Year by year, Cost of Revenue stood at $274.4 million in 2022, then plunged by 99.93% to $189077.0 in 2023, then soared by 86456.8% to $163.7 million in 2024, then declined by 2.35% to $159.8 million in 2025, then gained by 4.46% to $166.9 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $166.9 million, $159.8 million, and $160.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Curaleaf Holdings | 6.95 Bn | 6.95 Bn | 157.29 Mn | 166.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 166.94 Mn |
| Mar 31, 2026 | 166.94 Mn |
| Dec 31, 2025 | 159.81 Mn |
| Dec 31, 2025 | 159.81 Mn |
| Sep 30, 2025 | 160.50 Mn |
| Sep 30, 2025 | 160.50 Mn |
| Jun 30, 2025 | 161.97 Mn |
| Jun 30, 2025 | 161.97 Mn |
| Mar 31, 2025 | 151.06 Mn |
| Mar 31, 2025 | 151.06 Mn |
| Dec 31, 2024 | 163.66 Mn |
| Dec 31, 2024 | 163.66 Mn |
| Sep 30, 2024 | 170.01 Mn |
| Sep 30, 2024 | 170.01 Mn |
| Jun 30, 2024 | 181.82 Mn |
| Jun 30, 2024 | 181.82 Mn |
| Mar 31, 2024 | 178.03 Mn |
| Mar 31, 2024 | 178.03 Mn |
| Dec 31, 2023 | 189,077.00 |
| Dec 31, 2023 | 189,077.00 |